Akari Therapeutics
IPO
- Headquarters
- London, Massachusetts
- Employees
- 1–10
- Founded
- 2012
- Business Model
- B2B
- Website
- akaritx.com
- Total Funding
- $14.6M
- Last Round
- $5.0M Venture RoundDec 2025
About
Akari Therapeutics is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) with a novel spliceosome-targeting payload (PH1). The company's lead program, AKTX-101, is advancing toward a Phase 1 first-in-human clinical trial. Akari is listed on Nasdaq (AKTX) and operates from New York and Boston.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account